07:56 AM EDT, 10/10/2024 (MT Newswires) -- Tempest Therapeutics ( TPST ) said Thursday it is working with Roche to advance amezalpat into a phase 3 trial in combination with atezolizumab and bavacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma.

As part of the agreement, Roche will provide atezolizumab worldwide, while Tempest will sponsor and lead the trial, Tempest said, adding that it retains full commercial and development rights to amezalpat.

Tempest shares were up more than 27% in recent premarket activity Thursday.

Price: 1.7200, Change: +0.37, Percent Change: +27.41